David Noel Sheppard, PhD - “Single-channel studies of CFTR: Rescuing faulty channels in cystic fibrosis with targeted therapeutics”
- When Jan 16, 2024 from 12:00 PM to 01:15 PM (Europe/Berlin / UTC100)
- Where Tigem Auditorium Angelo Maramai
- Contact Name Luis Galietta
- Contact Phone 08119230659
-
Add event to calendar
iCal
- https://www.tigem.it/newsroom/seminars/david-noel-sheppard-phd-201csingle-channel-studies-of-cftr-rescuing-faulty-channels-in-cystic-fibrosis-with-targeted-therapeutics201d
- David Noel Sheppard, PhD - “Single-channel studies of CFTR: Rescuing faulty channels in cystic fibrosis with targeted therapeutics”
- 2024-01-16T12:00:00+01:00
- 2024-01-16T13:15:00+01:00
David Noel Sheppard, PhD
Professor of Physiology,
University of Bristol,
Bristol, UK
Short CV
Abstract
The genetic disease cystic fibrosis (CF) is caused by dysfunction of the epithelial anion channel, cystic fibrosis transmembrane conductance regulator (CFTR). Orally-bioavailable CFTR modulators termed CFTR correctors and potentiators that directly target defective CFTR anion channels have transformed the treatment of CF. This presentation will first review how the predominant CF-causing CFTR variant, F508del, disrupts the plasma membrane expression, stability and function of CFTR. Then, single-channel studies to elucidate how the triple combination therapy elexacaftor-tezacaftor-ivacaftor rescue the F508del-CFTR chloride channel will be discussed.
Professor of Physiology,
University of Bristol,
Bristol, UK
Short CV
Abstract
The genetic disease cystic fibrosis (CF) is caused by dysfunction of the epithelial anion channel, cystic fibrosis transmembrane conductance regulator (CFTR). Orally-bioavailable CFTR modulators termed CFTR correctors and potentiators that directly target defective CFTR anion channels have transformed the treatment of CF. This presentation will first review how the predominant CF-causing CFTR variant, F508del, disrupts the plasma membrane expression, stability and function of CFTR. Then, single-channel studies to elucidate how the triple combination therapy elexacaftor-tezacaftor-ivacaftor rescue the F508del-CFTR chloride channel will be discussed.